Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $226.00
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective lifted by Barclays from $185.00 to $226.00 in a research report sent to investors on Friday morning, Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock. SRPT has been the topic of a number of other reports. Needham & Company LLC […]
More Stories
Aleph Zero (AZERO) Price Down 16.8% Over Last 7 Days
Aleph Zero (AZERO) traded 6.3% lower against the dollar during the 24 hour period ending at 13:00 PM ET on...
JUNO (JUNO) Reaches 1-Day Trading Volume of $83,727.18
JUNO (JUNO) traded down 4.5% against the U.S. dollar during the 24-hour period ending at 13:00 PM E.T. on July...
McDonald’s Co. (NYSE:MCD) Shares Purchased by Core Wealth Partners LLC
Core Wealth Partners LLC lifted its position in McDonald’s Co. (NYSE:MCD – Free Report) by 4.2% during the first quarter,...
Casper Market Cap Tops $256.44 Million (CSPR)
Casper (CSPR) traded up 1.5% against the US dollar during the twenty-four hour period ending at 13:00 PM ET on...
Atomic Wallet Coin Hits 24-Hour Trading Volume of $1,772.81 (AWC)
Atomic Wallet Coin (AWC) traded down 4.1% against the dollar during the 24 hour period ending at 13:00 PM E.T....
ZRC Wealth Management LLC Acquires 4,870 Shares of Avantis International Equity ETF (NYSEARCA:AVDE)
ZRC Wealth Management LLC grew its position in Avantis International Equity ETF (NYSEARCA:AVDE – Free Report) by 3.7% in the...